跳至主要内容
临床试验/NCT01454635
NCT01454635已完成不适用

Treatment Response Study of Sertraline to Treat Japanese Major Depressive Disorder

Showa University1 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2008年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
96
试验地点
1
主要终点
Hamilton Rating Scale for Depression

研究概览

简要总结

The purpose of this study is to predict and visualize sertraline treatment response in major depressive disorder with clinical symptoms, demographic and stress state, personality, eight genetic polymorphisms at baseline.

详细描述

While only about 50% of patients respond to first treatment in major depressive disorder, 30-40% did not remit after continuous 1 year treatment. However, patients must remain on their prescribed medications for at least 4 weeks without knowing whether the particular antidepressant will be effective. Studies have suggested a number of predictors of treatment response, but varying degrees of success and nearly all with poor prognostic sensitivity and specificity. The investigators investigated clinical symptoms, demographic and stress state, personality and genetic polymorphisms in patients of major depressive disorder treated with sertraline and performed multivariate analysis to extract the predicting factors. Moreover, the investigators tried to visualize weight of variables and pathway one another.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • clinical diagnosis of Major Depressive Disorder
  • Must be able to swallow tablets

排除标准

  • breastfeeding

研究组 & 干预措施

Sertraline, Treatment response

Other

dosage, frequency and duration

干预措施: Sertraline (Drug)

结局指标

主要结局

Hamilton Rating Scale for Depression

时间窗: 8 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gentaro Nishioka

Tokyo Metropolitan Police Hospital, Department of Psychiatry, Principal Investigator

Showa University

研究点 (1)

Loading locations...

相似试验